B Cell Induction in Pediatric Lung Transplantation

Status Completed

Clinical Trial Summary

In this study, doctors are trying to see if a study drug called rituximab (Rituxan®) will lower the number of B cells in the body. Doctors are also trying to see if decreasing B cells with rituximab (Rituxan®) can prevent injury to the transplanted lung. This treatment has been studied in other types of solid organ transplants.

Clinical Trial Description

Patients who receive a lung transplant are at risk for rejection of the transplanted lung(s). Rejection occurs when the new lung triggers the body's defense (immune) system. When the immune system is triggered special cells are sent out to destroy the new lung and eventually the lung may not be able to function as it should. These special cells include B cells. B cells are an important part of the immune system and help the body fight infection. One way B cells fight infection is by producing antibodies. B cells and the antibodies they produce are involved in some kinds of rejection after organ transplantation. ;

Study Design

Related Conditions & MeSH terms

Lung Transplant

Clinical Trial Details

NCT number	NCT02266888
Study type	Interventional
Source	National Institute of Allergy and Infectious Diseases (NIAID)
Contact
Status	Completed
Phase	Phase 2
Start date	January 22, 2015
Completion date	June 30, 2019

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05404919` - Utilization of Hepatitis B Virus NAT+ Donors for Hepatitis B Vaccinated Lung Transplant Candidates	Phase 2
Completed	`NCT03299504` - Factors Predicting Success in Lung Transplant Recipients Who Have Undergone Intensive Post-operative Rehabilitation
Completed	`NCT00755781` - Study of Cyclosporine Inhalation Solution (CIS) in Improving Bronchiolitis Obliterans Syndrome-Free Survival Following Lung Transplantation	Phase 3
Recruiting	`NCT05547698` - A Study of Venoarterial ECMO vs Off-Pump Bilateral Orthotopic Lung Transplantation	N/A
Terminated	`NCT03207399` - Lung Transplantation in Chronic HCV Infection With Post Transplant EPCLUSA Treatment	Phase 4
Completed	`NCT03300882` - PREDICT Cytomegalovirus (CMV)
Recruiting	`NCT05101460` - An All Comers Registry For Normothermic Ex Vivo Lung Perfusion (EVLP) as Assessment of Donor Lungs for Transplant
Completed	`NCT03150095` - Health Coaching to Improve Self-Management in Thoracic Transplant Candidates	N/A
Completed	`NCT04420195` - Envarsus XR in Lung Transplant	Phase 2
Recruiting	`NCT02235610` - Use of Ex Vivo Lung Perfusion (EVLP) in Reconditioning Marginal Donor Lungs for Transplantation	N/A
Not yet recruiting	`NCT06066229` - Identification of Patient Important Outcomes in Lung Transplantation
Recruiting	`NCT04601818` - Planned Semi-Elective Lung Tx Study	N/A
Recruiting	`NCT03072589` - Study to Evaluate Adenosine 2A Receptor Agonist (Regadenoson) in Patients Undergoing Lung Transplantation	Phase 1
Completed	`NCT01963780` - International EXPAND Lung Pivotal Trial	N/A
Recruiting	`NCT05671887` - DREAM: Double Lung Transplant REgistry Aimed for Lung-limited Malignancies
Completed	`NCT03987113` - Impact of Cold Ischemia on Pulmonary Endothelial Dysfunction in Ex-vivo Pulmonary Reconditioning
Recruiting	`NCT02748798` - Developing Optimal Parameters for Hyperpolarized Noble Gas and Inert Fluorinated Gas MRI of Lung Disorders	Early Phase 1
Completed	`NCT03167528` - Contribution of Learning and Practice of Different Complementary Therapies in Pulmonary Transplant Patients	N/A
Active, not recruiting	`NCT04244734` - Implementation of an Early Rehabilitation Program for the Patient With Lung Transplantation: From the ICU to Home.	N/A
Active, not recruiting	`NCT01365429` - Novel Lung Trial: Normothermic Ex Vivo Lung Perfusion (Evlp) As An Assessment Of Extended/Marginal Donor Lungs	N/A